Crossmark

TRIM11 is upregulated in esophageal cancer and promotes tumor progression through modulation of the β-catenin signaling pathway

Published Online: 2026-05-14

Published Print: 2026-12

Authors

Li, Wei

Lan, Qingzhi

Lu, Shimin

Dong, Weiguo https://orcid.org/0000-0002-4228-6508
Funding

Funding for this research was provided by:

Hubei Provincial Key Research and Development Program (2020BCA066)
License Information

Text and Data Mining valid from 2026-05-14

Version of Record valid from 2026-05-14
More Information

Article History

Received: 8 February 2026

Revised: 4 April 2026

Accepted: 4 May 2026

First Online: 14 May 2026

Declarations

:

: Animal experiments were reviewed and approved by the Medical Ethics Committee of Renmin Hospital of Wuhan University(approval number: IACUC-20201212).

: The authors declare no competing interests.

: Not applicable.

Document is current